NKTT Gains Access to BioWa's Platform for Use in Antibody R&D
NKT Therapeutics (NKTT) is tapping into BioWa's Potelligent® Technology for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. NKTT will use this platform to research and develop antibodies targeting natural killer T cells. BioWa will receive an up-front payment, development milestone payments, and royalties on products.
Potelligent reportedly improves potency and efficacy of antibody therapeutics by enhancing ADCC. It involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell.